Coherus Oncology (CHRS) EBITDA (2013 - 2026)

Coherus Oncology has disclosed EBITDA across 14 years of filings, most recently posting -$36.2 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$36.2 million, up 20.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.2 million (up 83.55% YoY), and the FY2025 annual result was -$38.5 million, up 80.74% from the prior year.
• EBITDA came in at -$36.2 million for Q1 2026 at Coherus Oncology, down from $96.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $96.8 million in Q4 2025 to a low of -$80.9 million in Q1 2022.
• The 5-year median for EBITDA is -$45.4 million (2025), against an average of -$43.2 million.
• Across the five-year window, EBITDA plunged 145.37% in 2022 and surged 313.29% in 2025, its largest moves.
• Coherus Oncology's EBITDA stood at -$51.5 million in 2022, then sank by 33.81% to -$68.9 million in 2023, then jumped by 34.14% to -$45.4 million in 2024, then soared by 313.29% to $96.8 million in 2025, then slumped by 137.35% to -$36.2 million in 2026.
• The last three EBITDA figures came in at -$36.2 million (Q1 2026), $96.8 million (Q4 2025), and -$44.3 million (Q3 2025), per Business Quant data.